In this study, it predicted that TP53, AKT1, and CTNNB1 were the core targets of NX compounds, indicating that NX may exert its pharmacological therapeutic effect against HF by targeting TP53, AKT1, and CTNNB1. The gene discussed is TP53; the disease is hydrops fetalis.